MGC Diagnostics Corporation to Report Fourth Quarter and Fiscal Year 2012 Financial Results on Wednesday, December 19, 2012

  MGC Diagnostics Corporation to Report Fourth Quarter and Fiscal Year 2012
              Financial Results on Wednesday, December 19, 2012

PR Newswire

SAINT PAUL, Minn., Dec. 11, 2012

SAINT PAUL, Minn., Dec. 11, 2012 /PRNewswire/ -- MGC Diagnostics Corporation
(NASDAQ: MGCD) (formerly Angeion Corporation (NASDAQ:ANGN)), a global medical
technology company, today scheduled a conference call to discuss its financial
results for the fourth quarter and fiscal year 2012, ended October 31, 2012.
The call will be at 11:00 a.m. ET on Wednesday, December 19, 2012. The Company
will report financial results for the fourth quarter and fiscal year 2012
before the markets open on Wednesday, December 19, 2012.

(Logo: http://photos.prnewswire.com/prnh/20120821/LA60189LOGO)

Participants can dial (877) 317-6789 or (412) 317-6789 to access the
conference call, or listen via a live Internet webcast on the Company's
website at www.mgcdiagnostics.com. A replay of the conference call will be
available by dialing (877) 344-7529 or (412) 317-0088, confirmation code
10022073, through December 26, 2012. A webcast replay of the conference call
will be accessible on the Company's website at www.mgcdiagnostics.com for 90
days.

About MGC Diagnostics

MGC Diagnostics Corporation (NASDAQ: MGCD), (formerly Angeion Corporation), is
a global medical technology company dedicated to CardioRespiratory health
solutions. MGC Diagnostics develops, manufactures and markets non-invasive
diagnostic systems. This portfolio of products provides solutions for disease
detection, integrated care, and wellness across the spectrum of
CardioRespiratory healthcare. The Company's products are sold internationally
through distributors and in the United States through a direct sales force
targeting heart and lung specialists located in hospitals, university-based
medical centers, medical clinics, physicians' offices, pharmaceutical
companies, medical device manufacturers, and clinical research organizations
(CROs). For more information about MGC Diagnostics, visit
www.mgcdiagnostics.com.

Contact: Robert M. Wolf             Joe Dorame, Robert Blum, Joe Diaz
         MGC Diagnostics Corporation Lytham Partners, LLC
         Chief Financial Officer    (602) 889-9700
         (651) 484-4874             mgcd@lythampartners.com

SOURCE MGC Diagnostics Corporation

Website: http://mgcdiagnostics.com